# The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression

> **NCT07662473** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Experimental Group

## Key facts

- **NCT ID:** NCT07662473
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662473, "The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07662473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*